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Abstract
Background: While many sex differences in structure and function of the mammalian brain have been described,
the molecular correlates of these differences are not broadly known. Also unknown is how sex differences at the
protein level are perturbed by mutations that lead to intellectual disability (ID). Down syndrome (DS) is the most
common genetic cause of ID and is due to trisomy of human chromosome 21 (Hsa21) and the resulting increased
expression of Hsa21-encoded genes. The Dp(10)1Yey mouse model (Dp10) of DS is trisomic for orthologs of 39
Hsa21 protein-coding genes that map to mouse chromosome 10 (Mmu10), including four genes with known sex
differences in functional properties. How these genes contribute to the DS cognitive phenotype is not known.
Methods: Using reverse phase protein arrays, levels of ~100 proteins/protein modifications were measured in the
hippocampus, cerebellum, and cortex of female and male controls and their trisomic Dp10 littermates. Proteins
were chosen for their known roles in learning/memory and synaptic plasticity and include components of the
MAPK, MTOR, and apoptosis pathways, immediate early genes, and subunits of ionotropic glutamate receptors.
Protein levels were compared between genotypes, sexes, and brain regions using a three-level mixed effects model
and the Benjamini-Hochberg correction for multiple testing.
Results: In control mice, levels of approximately one half of the proteins differ significantly between females and
males in at least one brain region; in the hippocampus alone, levels of 40 % of the proteins are significantly higher
in females. Trisomy of the Mmu10 segment differentially affects female and male profiles, perturbing protein levels
most in the cerebellum of female Dp10 and most in the hippocampus of male Dp10. Cortex is minimally affected
by sex and genotype. Diverse pathways and processes are implicated in both sex and genotype differences.
Conclusions: The extensive sex differences in control mice in levels of proteins involved in learning/memory
illustrate the molecular complexity underlying sex differences in normal neurological processes. The sex-specific
abnormalities in the Dp10 suggest the possibility of sex-specific phenotypic features in DS and reinforce the need
to use female as well as male mice, in particular in preclinical evaluations of drug responses.
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Background
Sex differences in brain function and dysfunction are
well documented [1, 2]. Sex differences in learning strat-
egies, in responses to stress, and in the effects of stress
on learning have been described in both rodents and
humans; possibly contributing to these are differences in
adult neurogenesis that have been described in rodents
[2–4]. Neuropsychiatric disorders, such as schizophre-
nia, major depression, and post-traumatic stress dis-
order, show sex biases in incidence, age of onset, and/or
severity [5]. Neurodegenerative diseases also show sex
differences; notably, Alzheimer’s disease (AD) is more
common in women than men [6]. Sex differences are
also seen in efficacy and side effects of drugs used to
treat such disorders [7].
Sex differences are attributed at least in part to mo-
lecular events that occur during development and
throughout postnatal life in the regulation and levels of
sex hormones and their receptors [8, 9]. Sex differences
also exist in expression of some genes encoded by the X
chromosome. As many as 15 % of human X chromo-
some genes have been reported to escape silencing on
the inactive X, which may result in higher levels of ex-
pression in females of these X inactivation escape genes
[10–14]. Because sex hormone receptors and X inactiva-
tion escape genes together include transcription factors
and genes involved in post-translational protein modifi-
cations, effects of sex differences will propagate down-
stream to affect many pathways and cellular processes.
Indeed, in one comprehensive study where oligonucleo-
tide arrays were screened with RNA from >100 age-
matched female and male mice, of the ~4500 genes with
detectable expression in brain, ~600 (14 %) showed sig-
nificant differences in levels between sexes; ~350 were
higher in females and ~260 were higher in males [15].
Intellectual disability and Down syndrome
Intellectual disability (ID) affects 1–3 % of the popula-
tion worldwide [16]. For ID associated with genetic
causes, mutations in several hundred human genes have
been identified [17, 18]. Of these, ~100 are encoded by
the X chromosome, which contributes to the elevated
incidence of ID in males [19]. The most common gen-
etic cause of ID, however, is Down syndrome (DS), with
an incidence of 1 in ~700–1000 live births worldwide
[20, 21]. DS is caused by trisomy of all or part of the
long arm of human chromosome 21 (Hsa21q) and the
increased expression of trisomic genes. Hsa21q encodes
~160 proteins of diverse functions, ~50 members of the
keratin-associated protein family, multiple microRNAs,
and several hundred human-specific transcripts that
may be protein coding, functional RNAs, or transcrip-
tional noise [22, 23]. The neurological phenotype of DS
includes well-documented cognitive deficits in tasks
requiring a functioning hippocampus, executive func-
tion, and language processing [24–26]. Neuronal num-
bers and cellular morphology are abnormal in several
brain regions, including the hippocampus and cerebel-
lum. Of particular importance, now that the life span of
people with DS has increased to >60 years, is the univer-
sal development of the pathology of AD by age 30 and
the development in half of those with DS of an AD-like
dementia by the age of 50 [27]. While much has been
determined about the functions of some Hsa21 genes,
the true number and identity of all those contributing to
ID and AD in DS is not known. Sex differences in the
specifics of ID in DS, and whether these simply reflect
sex differences in the typical population, have not com-
monly been investigated.
Modeling DS in mouse and the Dp(10)1Yey
DS is difficult to model well in mouse, not only because it
is a contiguous gene syndrome with candidate genes span-
ning the length of Hsa21q but also because orthologs of
Hsa21 genes are distributed on segments of three mouse
chromosomes: the telomeric region of mouse chromosome
16 (Mmu16) and internal segments of mouse chromosome
17 (Mmu17) and mouse chromosome 10 (Mmu10) [22].
Many partial trisomy mouse models of DS have been cre-
ated, and each shows a unique constellation of DS-relevant
learning deficits, synaptic plasticity and cellular abnormal-
ities, and/or gene expression perturbations [28]. Little, how-
ever, has been determined regarding sex differences. Here,
we focus on the Dp(10)1Yey mouse model of DS (abbrevi-
ated Dp10). The Dp10 was generated by chromosomal
engineering to carry an internal duplication spanning the
39 Hsa21 orthologs mapping to Mmu10 [29]. Several of
these genes have been shown individually to have roles in
brain development and function, to modulate molecular
processes involved in AD, and/or to display sex differences
in their functional properties and consequences. The
following genes are examples: (i) the adenosine deaminase
2 (ADAR2) gene encodes a protein that modifies the
activities of glutamate, gamma-aminobutyric acid
(GABA), and serotonin receptors by means of pre-
mRNA editing [30–33]; a null mutation of ADAR2
results in deficits in the auditory startle response and
hearing impairment in male, but not female, mice
[34]; (ii) the Ca-binding protein, S100B, stimulates
neurite outgrowth and the activation of microglia and,
when overexpressed, exacerbates AD-like pathology in a
mouse model of AD [35, 36]; (iii) the cysteine protease in-
hibitor, cystatin B, CSTB, when mutated causes a form of
progressive myoclonic epilepsy [37, 38] and, when knocked
down, rescues AD-like features in a mouse model of AD;
(iv) the collagen 18A1 C-terminal fragment, endostatin,
functions in synaptogenesis in the cerebellum [39] and, at
least in vitro, can inhibit neurite outgrowth and neuronal
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migration [40]; (v) the protein methytransferase, PRMT2,
and (vi) the small ubiquitin-like modifier protein, SUMO3,
methylate and sumoylate, respectively, steroid hormone
receptors;—both modifications contribute to the regulation
of activity of estrogen, androgen, progesterone, and other
receptors that function during development and in the
adult brain [41–43]; and (vii) the transient receptor
potential cation channel, subfamily M, member 2,TRPM2,
contributes to N-methyl-D-aspartate (NMDA)-mediated
metaplasticity in hippocampal synapses [44]; a null muta-
tion of TRPM2 protects male, but not female, mice from
damage due to ischemia with a mechanism that involves
the androgen receptor [45]. Because orthologs of these
genes map to Hsa21, it is reasonable to predict that over-
expression in DS would impact levels and/or activities of
many non-Hsa21 proteins, and consequently, brain struc-
ture and function, and that it would do so with direct or
indirect sex differences.
Overexpression at the RNA level of ADAR2, S100B,
and TRPM2 has been demonstrated in the Dp10 mice
[29]. This was not, however, associated with deficits in
learning and memory (LM) when mice 2–4 months old
were tested in the Morris water maze (MWM) and con-
text fear conditioning (CFC), nor with abnormal long-
term potentiation (LTP) [46]. In contrast to behavioral
and electrophysiological data, when levels of 26 non-
Hsa21proteins relevant to AD were measured in the
hippocampus of ~8-month-old Dp10 mice, levels of 12
differed significantly from those in controls [47]. Only
male mice were reported in both these studies.
To investigate sex differences in molecular features
that may underlie normal LM and perturbations that
may contribute to impaired LM in DS, we describe here
expression levels of ~100 proteins in the hippocampus,
cortex, and cerebellum of cohorts of male and female
control mice and their age- and sex-matched trisomic
littermates from the Dp10 line. The proteins include
components of the MAPK, MTOR, and apoptosis sig-
naling pathways, immediate early gene (IEG) proteins,
subunits of ionotropic glutamate receptors, and add-
itional proteins involved in synaptic plasticity and/or
known to be mutated in subsets of patients with ID or
in mouse mutants showing LM deficits or abnormal in
patients with AD or mouse models of AD. We show
that, in the hippocampus of control mice, levels of al-
most half of these proteins differ between male and fe-
male mice and that in each case, the level is higher in
females than in males. In contrast, sex influences on
levels of the same proteins are minimal in the cortex
and cerebellum. Trisomy-associated perturbations are
also sex-specific, with hippocampus most affected in
male Dp10 and cerebellum most affected in female
Dp10. The observation that females and males differ in
their baseline profiles of proteins critical to learning and
memory suggests that molecular responses to the stimu-
lation of learning will differ. The data also suggest that
Hsa21 genes with orthologs on Mmu10 may influence,
positively or negatively, cognitive features in people with
DS, and that the molecular basis of these features, and
their modulation by pharmacological treatment, will dif-
fer between males and females.
Methods
Mice
The Dp(10)1Yey mice [29, 46], originally a gift from Y.
Yu (Roswell Park, New York), were maintained by
breeding trisomic males to non-trisomic females on a
C57BL/6JEi background. The mice were housed at the
University of Colorado Denver in a room with HEPA-
filtered air and a 14:10 light:dark cycle and fed with 6 %
fat diet and acidified (pH 2.5–3.0) water ad libitum. All
procedures were approved by the University of Colorado
Institutional Animal Care and Use Committee and per-
formed in accordance with the National Institute of
Health guidelines for the care and use of animals in re-
search. Seven litters of mice were used, comprising 10
female control mice, 7 female Dp10 trisomic mice, 9
male control mice, and 10 male Dp10 trisomic mice. Lit-
termates (Additional file 1), separated by sex, were
housed in the same cage. Female mice (with two excep-
tions noted) were in diestrus. All mice were naïve, aged
7–9 months, and sacrificed between 12 p.m. and 2 p.m.
to maintain a consistent circadian time point.
Genotyping of mice
DNA was prepared from a 1-mm tail snip by lysis in
50 nM NaOH at 98 °C for 1 h, followed by neutralization
with 1 M Tris Base (pH 8.0). Lysates were stored at −20 °C
until use. Mice were genotyped by standard PCR using the
following primer pairs: control gene reverse primer 5-′
CTAGGCCACAGAATTGAAAGATCT- 3′ and forward
primer 5′GTAGGTGGAAATTCTAGCATCATCC 3′; tri-
somic gene forward primer 5′GGCGAACGTGGCGA
GAAA 3′ and reverse primer 5′CCTGCTGCCAAGC
CATCAG 3′.
Tissue processing and protein lysate preparations
To preserve protein phosphorylation, mice were sacri-
ficed by cervical dislocation without anesthetic. The
whole brain was removed, immediately snap frozen in li-
quid nitrogen, and stored at −80 °C. For lysate prepar-
ation, the brains were removed from the freezer and,
without thawing, rapidly heated to 95 °C under vacuum
in the Stabilizor T1 (Denator, AB) as described previ-
ously (48). The cortex, hippocampus, and cerebellum
were dissected out, weighed, placed in 10 volumes of
IEF buffer (8 M urea, 4 % CHAPS, 50 mM Tris) and ho-
mogenized by sonication with three bursts 5 s long in a
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Branson Sonic Power Co. (Danbury, CT). Lysates were
centrifuged to remove debris, and the protein concentra-
tion of the cleared supernatant was determined using
the 660 nM Protein Assay Kit (Pierce); all sample pro-
tein concentrations were 9–11 mg/ml. Information for
each mouse, age, littermates, and tissue weight is pro-
vided in Additional file 1. Gonadal hormone levels were
not measured.
Antibodies and validation for RPPA
Proteins screened for expression level are listed in
Additional file 2. Functional annotation as ID or LM
and antibody information regarding supplier, catalog num-
ber, and dilution factor are also provided. Reverse phase
protein arrays (RPPA) require highly specific antibodies.
Prior to use, each lot of each antibody was verified by
Western blot using mouse brain lysates to show only clean
band(s) of explainable size, with no non-specific bands
present. All secondary antibodies (IgG; anti-goat, rabbit,
and mouse) have been shown previously to produce sig-
nals that are less than 5 % above local background when
incubated with an RPPA slide in the absence of any pri-
mary antibody; signals of these levels are too low to be re-
liably quantitated and were ignored in data analysis.
Array assembly and printing
Each sample lysate was prepared in 5 dilutions, neat plus
4 serial dilutions with a 0.8 dilution factor, and 1 buffer
control, in a 384-well V-shaped ABgene plate (Thermo
Fisher Scientific, Rockford, IL). Samples were printed, in
triplicate, onto nitrocellulose-coated glass slides (Grace
Bio-Laboratories, Inc., Bend, OR) using an Aushon Bio-
Systems 2470 Arrayer (Aushon BioSystems, Billerica,
MA) with 185-μm pins and a single touch. The arrays
were produced in two major print runs and slides were
stored at 4 °C until further use.
Antibody detection and array staining
Procedures for array screening have been described pre-
viously [48]. Briefly, slides were incubated in blocking
solution 3 % BSA (Sigma, USA) in TBST (Tris-buffered
saline, 0.1 % Tween 20) for 4 h, followed by overnight
incubation at 4 °C with shaking with the primary antibody
(antibody dilutions are provided in Additional file 2:
Table S2). Detection of the bound primary antibody
was performed by incubation with the secondary anti-
body, Fluorescence Alexa Fluor 555 goat anti-mouse
or anti-rabbit or rabbit anti-goat (1:2000 dilution)
(Invitrogen, Carlsbad, CA), for 90 min at room
temperature. Slides were washed and dried, and sig-
nals were detected by scanning on a GenePix Pro
4000B array slide scanner (Axon Instruments, USA)
using GenePix 4.0 software or on a PerkinElmer Scan
Array Express HT Microarray Scanner (PerkinElmer
Inc., MA, USA). For normalization, total protein for
each spot was determined by staining three non-
sequential slides from each print run with SyproRuby
reagent (Invitrogen, CA, USA) following the manufac-
turer’s protocol.
Image analysis, quantification, normalization, and
statistical analysis
Signals on each slide were quantified using Scan Array Ex-
press software (PerkinElmer Inc., MA, USA) where the
antibody signal intensity for each spot was normalized to
the corresponding SyproRuby signal. Details of quantifica-
tion and review of data quality and reproducibility were as
described previously [48, 49, 50]. After removal of tech-
nical outliers, normalized protein values, transformed into
a natural log scale were used in statistical analysis. Mean
differences between genotypes (trisomy vs. control) and
sexes (female vs. male) were reported as a ratio and per-
cent, assessed using a hierarchical three-level mixed ef-
fects model to account for possible correlations and
variability between replicates and dilutions within each
sample. The Benjamini-Hochberg corrected p value <0.05
with a false discovery rate (FDR) of 5 % was considered
for overall statistical significance across the entirety of the
hypotheses. Results of all comparisons carried out for the
three brain regions are provided in Additional file 3.
For correlation analysis, data were reduced to one ob-
servation per mouse. Protein values for each brain re-
gion of each individual of each sex/genotype were used
to compute Spearman correlation coefficients. Graphs
for data from protein pairs with correlation coefficients
greater than 0.8 with p < 0.05 were inspected and corre-
lations with artifactually high r values (i.e., non-linear re-
lationships) were eliminated. All data analysis was
carried out using SAS® version 9.3 (SAS Institute Inc.,
Cary, NC).
Protein interaction networks
Protein interaction partners of each protein encoded in
the Dp10 trisomic segment for each of the proteins mea-
sured by RPPA and for proteins encoded on the X
chromosome that escape X inactivation [11–13] were ob-
tained from the IntACT (http://www.ebi.ac.uk/intact/),
HPRD (Human Protein Reference Database, http://
www.hprd.org/), and BioGRID (Biological General Reposi-
tory for Interaction Datasets, http://thebiogrid.org/) data-
bases. Subsets of primary and secondary interactions for
sex hormone receptors and proteins screened by RPPA
were retained for networks in Fig. 7. Networks were con-
structed using Cytoscape 3.0.2.
Results
The goals of the protein measurements were first to assess
sex differences in control mice and then to determine how
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trisomy of the Hsa21 syntenic region on Mmu10 influ-
ences both sex-dependent and sex-independent protein
profiles. A total of ~100 proteins/protein modifications
were screened in whole tissue lysates from the hippocam-
pus, cortex, and cerebellum of ~8-month-old mice. Four
pairwise comparisons were carried out for each brain re-
gion: (i) protein levels in control females were compared
to those in control males to determine sex differences nor-
mally present in the inbred C57BL/6JEi background, (ii)
levels in trisomic females were compared to those in triso-
mic males to determine if and how trisomy alters normal
sex differences, (iii) levels in trisomic males were com-
pared to those in control males, and (iv) levels in trisomic
females were compared to those in control females, to de-
termine sex-independent and sex-specific perturbations
caused by trisomy. Proteins measured included 18 compo-
nents of the MAP kinase pathway and 14 from the MTOR
pathway, 4 immediate early gene proteins, subunits of
ionotropic glutamate receptors, and a number of proteins
associated with AD. Fourteen proteins encoded by Hsa21,
4 of which are trisomic in the Dp10, were also measured.
Proteins were chosen because of their specific individual
importance, or the importance of the pathways in which
they function, to LM or synaptic plasticity or because they
have been shown to be abnormal in brains from people or
mouse models of DS, ID, or AD. Proteins include those
used in previous studies of the Tc1 mouse model of DS
and of the Ts65Dn with and without memantine treat-
ment and exposure to CFC [48, 49]. The complete list of
proteins is provided in Additional file 2, which includes
annotation as ID or mouse LM proteins. The use of RPPA
requires highly specific antibodies, and as a result, some
proteins of interest could not be assayed. Results of the
measurements of all proteins in the three brain regions in
all four comparisons are provided in Additional file 3. In
the following, we first summarize the general features of
the protein profiles with respect to sex and genotype dif-
ferences. We then discuss details for specific proteins and
pathways affected by sex and genotype.
Summary of sex differences
Figure 1a shows a Venn diagram illustrating, in control
mice, the distribution among brain regions of sex differ-
ences in protein expression. Of 102 proteins measured,
levels of 50 differed significantly between females and
males in at least one brain region. Hippocampus over-
whelmingly showed the most differences, 41. In addition,
levels of all of them were higher in females than males
and, for all but one protein, the differences were specific
to the hippocampus. In comparison, sex differences were
seen in only nine proteins in the cerebellum and in only
one protein in the cortex. A single protein differed in
Fig. 1 Distribution and overlaps of sex and genotype protein differences among brain regions. The number of proteins showing different levels
in at least one brain region and the total number of proteins measured in each comparison are provided in each panel. In each Venn diagram,
the total number of proteins that differed is indicated under the name of the brain region. Pink hippocampus (Hp), green cerebellum (Cb), blue
cortex (Cr). Arrows within the Venn diagram circles indicate increases and decreases in the respective ratios. H hippocampus, B cerebellum, C
cortex. a Female controls vs. male controls. b Female Dp10 vs. male Dp10. c Male Dp10 vs. male controls. d Female Dp10 vs. female controls
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more than one brain region: IL1B differed in both the
hippocampus and cerebellum, elevated in females in the
former and decreased in the latter.
Figure 1b illustrates the number of brain region sex
differences in protein expression in trisomic mice. In
contrast to control mice, the hippocampus showed the
fewest sex differences, only 15, and the cerebellum
showed the most, with 70 proteins differing in levels.
Also in contrast to controls, many proteins (a total of
27) showed significant sex differences in more than one
brain region. Specifically, only 43 of 70 showed sex dif-
ferences uniquely in the cerebellum; in both the cerebel-
lum and cortex, levels of 17 proteins were higher in
female trisomics than those in males, and three proteins
were higher in females in all three brain regions. Levels
of seven proteins differed between sexes in both the
hippocampus and cerebellum, but for six of these, the
differences were in opposite directions: levels were lower
in females than those in males in the hippocampus and
higher in the cerebellum.
It is evident from Fig. 1a, b that in addition to differ-
ences in brain region distribution, trisomic mice show a
greater total number of sex differences than do control
mice. As shown in Table 1, of ~300 measurements
(~100 in each of the three brain regions), a total of 51
measurements (~16 %) showed sex differences in control
mice, while 107 measurements (~35 %) differed between
sexes in trisomic mice. The magnitudes of the sex differ-
ences are also greater in trisomy. In control mice, 27 of
the 51 differences were in the range of 15–30 % and only
two differed by >30 %. In contrast, in trisomy, a majority
of differences in both the hippocampus (9 of 15) and cor-
tex (16 of 23) were in the range of 15–30 %, and in the
cerebellum alone 30 of 70 differences were >30 %. In
total, in trisomy, 88 of 107 differences were >15 %.
Therefore, trisomy not only changes the identity and
brain region distribution of the sexually dimorphic
proteins but also exacerbates the magnitude of sex
differences.
Perturbations due to trisomy
Figure 1c shows that, in the comparison of cohorts of
male mice, levels of 68 of 102 proteins were altered due
to trisomy. The hippocampus showed the most pertur-
bations, with 50 proteins altered. Of these, all but one
protein were increased in trisomy and 41 increases were
hippocampus-specific. In the cerebellum, 21 proteins
differed from controls, of which 11 were decreased and
2 were increased uniquely in the cerebellum. Few pro-
teins were altered in more than one brain region. Six
proteins were affected in both the hippocampus and
cerebellum, although levels of four changed in opposite
directions. In cortex, only eight proteins were altered,
four were decreased uniquely. A single perturbation was
common to all three brain regions: levels of the trisomic
protein S100B were increased by ~25–30 %. Perturba-
tions in additional Hsa21 orthologs are discussed below.
Figure 1d shows that, in trisomic females, levels of the
majority of proteins measured, 69 of 101, differed from
controls in at least one brain region. The distribution of
perturbations among brain regions, however, differed
from that in males. Only 18 perturbations were seen in
the hippocampus. Instead, the majority occurred in the
cerebellum where a total of 62 proteins were altered.
The cortex again was minimally affected, with only 13
proteins altered. Fourteen proteins were perturbed in
both the hippocampus and cerebellum, although only
eight were altered in the same direction. Eight proteins
were altered in both the cerebellum and cortex, and
seven of these were changed in the same direction in
both regions. As with male mice, S100B was elevated in
both the hippocampus and cerebellum (it was not mea-
sured in cortex). Also elevated in all three regions was
the non-Hsa21 protein AKT.
As shown in Table 2, the magnitudes of the perturba-
tions were greater in female trisomics than those in male
trisomics. More than half, 56 (60 %) of the total of 93 per-
turbations, seen in the three brain regions were in the
range of 15–30 % in female trisomics, compared with only
36 (45 %) of the total of 79 perturbations seen in male tri-
somics. Furthermore, 19 of 93 perturbations were >30 %
in females compared with only 6 of 79 in males.
Trisomy and sex effects on levels of Hsa21 orthologous
proteins
Levels of 14 Hsa21 orthologs were measured. Genes en-
coding three, S100B, PRMT2, and ADAR2, are trisomic
in the Dp10 mice. As shown in Fig. 2a, levels of S100B
are uniformly elevated by 20–30 % in trisomy in all three
brain regions and do not differ with sex in controls or tri-
somics. Levels of PRMT2 were not significantly affected
Table 1 Distribution among brain regions, direction (female vs.
male), and relative magnitude of sex differences
Hp (100) Cb (101) Cr (97) Total
Controls
Increased 41 1 1 51
Decreased 0 8 0
Δ15–30 % 23 4 0 27
Δ > 30 % 0 2 0 2
Trisomy
Increased 5 69 23 107
Decreased 10 0 0
Δ15–30 % 9 29 16 54
Δ > 30 % 0 30 4 34
Hp hippocampus, Cb cerebellum, Cr cortex. Δ, difference between sexes of the
same genotype. Brackets, total number of proteins measured
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by sex or by trisomy in the hippocampus (Additional file 3),
but in the cerebellum, they showed very large perturba-
tions, especially in females (Fig. 2b). In female control mice,
PRMT2 cerebellar levels were 25 % lower than those in
male controls; however, levels increased by 90 % in trisomic
female mice, but decreased by ~30 % in male trisomic mice.
This causes a reversal of sex differences in trisomy, where
levels in trisomic females are >100 % higher than those in
trisomic males. Figure 2c shows that in the hippocampus,
ADAR2 was elevated by 50 % in male Dp10 but not signifi-
cantly affected by trisomy in females. In the cerebellum,
ADAR2 was not affected by sex or trisomy (Additional
file 3) (ADAR2 was not measured in the cortex).
Proteins encoded by four Hsa21 genes that are not tri-
somic in the Dp10 were also affected by sex and/or tri-
somy with brain region specificities (Fig. 2d, e). In the
hippocampus of control mice, APP, ITSN1, RCAN1, and
PKNOX1 were elevated by 13–24 % in females com-
pared with males. Trisomy of the Mmu10 region re-
sulted in increases in the levels of these proteins in the
hippocampus of male mice but had no effect in females.
This sex-specific response served to erase sex differences
in trisomy. In the cerebellum, however, there were no
sex differences in levels of these proteins in control
mice; trisomy produced significant changes only in fe-
male mice, with the result that levels of APP, ITSN1,
and PKNOX1 were significantly higher in female Dp10
than in males (Fig. 2e).
Consistent with the overall modest sex and trisomy
effects on protein expression in cortex, perturbation
of Hsa21 protein levels were slight. Levels of S100B
were elevated in trisomy (PRMT2 and ADAR2 were
either unchanged or not measured in all samples).
Unique to cortex, however, sex comparisons showed
significantly higher levels in Dp10 females than Dp10
males of the Hsa21 orthologs TIAM1, CBS, and RRP1
(Additional file 4). These were largely a result of in-
creases in trisomy females compared to control fe-
males, with trisomy not affecting males.
Fig. 2 Sex and genotype differences in levels of selected Hsa21-encoded proteins. Bar graphs indicate the percent (%) increase or decrease in
each comparison. HP hippocampus, CB cerebellum, CR cortex, C controls, females vs. males; T trisomic (Dp10) females vs. Dp10 males; M male
Dp10 vs. male controls; F female Dp10 vs. female controls. Asterisk significant difference by three-level mixed effects model after Benjamini-Hochberg
correction, with 5 % false discovery rate. n, not measured. Error bars indicate the SEM. a–c Proteins are encoded by genes trisomic in the Dp10 mice.
d, e Genes encoding APP and ITSN1 map to Mmu16 and PKNOX1 maps to Mmu17 and are not trisomic in the Dp10
Table 2 Distribution among brain regions, direction (trisomic vs.
control) and relative magnitude of trisomic differences
Hp (100) Cb (101) Cr (97) Total
Females
Increased 11 62 11 93
Decreased 7 0 2
Δ15–30 % 8 40 8 56
Δ > 30 % 3 14 2 19
Males
Increased 49 4 1 79
Decreased 1 17 7
Δ15–30 % 24 10 2 36
Δ > 30 % 4 2 0 6
Hp hippocampus, Cb cerebellum, Cr cortex. Δ, difference between trisomic and
control of same sex. Brackets, total number of proteins measured
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There are two important observations here: levels of
some proteins encoded by Hsa21 orthologous genes that
are not trisomic are affected by trisomy of the Mmu10
region. These genes include APP that has been well-
studied for its role in AD. The effects on these proteins
are sex-biased, which means that many would be missed
in studying only male cohorts.
MTOR pathway
In the hippocampus, 14 components of the MTOR path-
way were measured, including 7 phosphoproteins. Re-
sults are shown in Fig. 3. Levels of five components
differ between female and male controls, showing differ-
ences of 11–20 %. In Dp10 males, levels of 10 of the 14
components were increased with respect to control
males; only pEIF4B, GSK3B, P70S6, and pS6 were not af-
fected. The opposite occurred in Dp10 females: levels of
12 of 14 components were not altered, and only AKT
and pP70S6 were increased with respect to control fe-
males. The scenario in the cerebellum is very different.
There were no significant sex differences in control mice,
and only three proteins, AKT, P70S6, and pGSK3BY216
were altered in male trisomic mice. However, in female
trisomic mice, levels of 9 of 13 components (S6 was not
Fig. 3 Sex and genotype differences in levels of components of the MTOR pathway in the hippocampus and cerebellum. Legend as in Fig. 2
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measured) were significantly increased; of these, AKT and
pAKT were increased by 66 and 45 %, respectively, and
pMTOR and pS6 each by ~30 %. As a result, levels of 12
of 13 components of the MTOR pathway were higher in
the cerebella of female Dp10 mice than male; only AKT
shows similar levels in male and female trisomics. Thus,
the picture of perturbations in MTOR is strongly sex,
genotype, and brain region-specific.
MAPK pathway
In comparison to MTOR, perturbations in the MAPK
pathway are minimal. In the hippocampus, four compo-
nents differed between male and female control mice,
pERK, pELK, RSK, and pRSK, and only pBRAF and pERK
showed sex differences in Dp10 mice. Only 5 of 14 com-
ponents of the classical MAPK pathway were perturbed,
all increased, in male Dp10, and only one was altered in
female Dp10. Data are shown in Additional file 4.
AD-related proteins
We previously reported in the hippocampus of male Dp10
mice [47] measurement of 26 proteins that had shown ab-
normal levels in brains of patients with AD and/or mouse
models of AD. We extended this analysis here to add-
itional brain regions and cohorts of female mice. In con-
trol mice, 10 proteins showed sex differences in the
hippocampus, all elevated in females (Additional files 3
and 4). Among them were APP, ERBB4, pSRC, IL1B,
pNUMB, and CASP3, proteins that were also perturbed in
male Dp10. When trisomic females were compared with
control females, however, levels of only 4 of the same 26
proteins were abnormal, and only pTau and α-synuclein
were perturbed in both male and female Dp10. Levels of
four proteins, CDK5, pGSK3BY216, IL1B, and nNOS,
showed sex differences in trisomic mice. Data are
provided in Additional file 3, and a subset is shown
in Additional file 4.
Data from the cerebellum again present a very differ-
ent picture. Levels of only four of the 26 AD-related pro-
teins, CDK5, IL1B, NR1 and NR2B, differed between
sexes in controls, while the majority, 18 of 26, differed
between sexes in trisomic mice. Levels of nine proteins
were altered in male Dp10, and 16 were altered in fe-
male Dp10. Perturbations in the levels of five proteins,
CDK5, pGSK3BY216, NR1, P35/25, and pNUMB, were
of the same magnitude in both male and female triso-
mics, but opposite in direction, decreased in males and
increased in females relative to their respective controls.
These data are shown in Additional file 4.
Sex and genotype effects in the cortex
Compared with hippocampus and cerebellum, protein
levels in the cortex showed few sex differences and
genotype perturbations. However, as shown in Fig. 4, the
perturbations that did occur affect proteins of particular
interest to LM and brain function, and the differences
were both unique to females and strong. For example,
levels of pCAMKII were increased by 50 % in female
Dp10, pS6 and PP2A by 35 %, and pJAK2 and pPKCG,
each by 25 %.
Relationships between brain regions
We compared protein levels between brain regions in
controls and asked how these relationships changed, or
not, with trisomy. The bar graphs in Fig. 5 show the sig-
nificant differences between the hippocampus and cere-
bellum in the levels of NMDAR subunits and the
components of the MTOR pathway. A positive ratio in-
dicates higher levels in the hippocampus, and a negative
ratio indicates higher levels in the cerebellum.
Figure 5a shows data for NMDAR subunits and related
proteins in female and male control mice. Overall, the
patterns are very similar. With the exception of pNR2A,
levels of all NMDAR subunits, plus TRKA and PSD95,
Fig. 4 Sex and genotype differences in levels of selected proteins in cortex. Legend as in Fig. 2
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are significantly greater in the hippocampus, and by
similar magnitudes, in both females and males. These re-
lationships are preserved even when protein levels differ
between sexes, e.g., for NR1 and NR2B. Similarly, levels
of GLUR4, NUMB, and pNUMB are higher in the cere-
bellum than those in the hippocampus, in both females
and males. For only three proteins, GLUR3, BDNF, and
SNCA, the higher levels in female hippocampus vs. those
Fig. 5 Ratio of protein levels in hippocampus and cerebellum. a NMDAR subunits and related proteins in female and male control mice.
b NMDAR subunits and related proteins in female and male Dp10 mice. c Components of the MTOR pathway in female and male control mice.
d Components of the MTOR pathway in female and male Dp10 mice. Y axis % difference in hippocampus vs. cerebellum. Black bars significant
difference, white bars non-significant difference
Block et al. Biology of Sex Differences  (2015) 6:24 Page 10 of 18
in male hippocampus result in modest differences in the
hippocampus and cerebellum levels between sexes.
Figure 5b shows results of the same analysis in triso-
mic mice. For both female and male Dp10, the patterns
of proteins that are higher in the hippocampus and
higher in the cerebellum are similar to those in their
sex-matched controls. Notably, however, in female
Dp10, the magnitudes of the differences are smaller, e.g.,
levels of NR1 and pNR1 are 100 and ~75 % higher in
the hippocampus than those in the cerebellum in triso-
mic females but ~170 and ~150 % higher in the hippo-
campus in controls. This reflects the predominant
perturbation of protein levels specific to the cerebellum
in trisomic females and the relatively few perturbations
in hippocampus. Conversely, in male Dp10 mice, the
levels of differences between brain regions are generally
higher than those in male controls, e.g., levels of NR2B
and PSD95 are ~250 % higher in the hippocampus than
those in the cerebellum in male Dp10, but only ~170
and ~150 % higher in male controls. This in turn reflects
the effects of trisomy in male Dp10 on protein levels in
the hippocampus.
Figure 5c, d present a similar analysis for components
of the MTOR pathway. For both female and male con-
trol mice (Fig. 5c), the differences in protein levels be-
tween the hippocampus and cerebellum are smaller than
those for NMDAR subunits and levels of the majority of
proteins are lower in the hippocampus than those in the
cerebellum. There is, however, an overall similarity in
patterns. In particular, levels of PI3K, pAKT, pGSK3BS9,
and P70S6 through RAPTOR are all lower in the hippo-
campus, and only PTEN is higher (and GSK3B in
females).
In Dp10 females, most components of the MTOR
pathway were increased in the cerebellum, but not per-
turbed in the hippocampus, relative to female controls,
and this is reflected in the magnitudes of the bar graphs
in Fig. 5d. Conversely, in male Dp10, perturbations were
largely seen as increased levels in the hippocampus rela-
tive to controls. As a result, while the pattern in Fig. 5d
looks very different from that of the male controls, it is
consistent with trisomy perturbations.
Results of a similar analysis of MAPK components are
shown in Additional file 4.
In prior work, correlations among functionally related
proteins were noted in the hippocampus of Tc1 and
Ts65Dn mice [48, 49]. In Fig. 6, we show patterns of cor-
relations among components of the MTOR pathway in
all three brain regions of the four genotype/sex groups
of mice. The strongest patterns of correlations are seen
in male control mice, where levels of RAPTOR, ERBB4,
AMPKA, pMTOR, and pEIF4B are correlated in all
three brain regions, and levels of pAKT are correlated in
the cerebellum and cortex (Fig. 6a). In female controls,
most of these correlations are not present in the hippo-
campus (Fig. 6c). In the Dp10, correlations in male mice
are largely preserved in the cerebellum, but variously
lost in both the hippocampus and cortex. In female
Dp10, most of the correlations seen in controls in the
cerebellum are lost, leaving only levels of ERBB4 and
AMPKA correlated, likely as a consequence of the per-
turbation of protein levels in this brain region. In con-
trast, Dp10-specific correlations among the proteins
have appeared in the hippocampus. The biological sig-
nificance of the presence, and absence, of correlations is
not obvious, but overall, their sexual dimorphism is con-
sistent with dimorphic levels of protein expression.
Discussion
Levels of ~100 proteins/protein modifications were mea-
sured in the hippocampus, cerebellum, and cortex of co-
horts of adult female and male mice. Cohorts included
mice trisomic for the Mmu10 region syntenic with
Hsa21 and their littermate controls. Analysis uncovered
both sex and genotype, brain region-specific differences
in protein expression. In control mice, levels of half the
proteins differed between females and males in at least
one brain region, and in the hippocampus alone, expres-
sion levels of 41 proteins were significantly higher in fe-
males than those in males. Levels of only nine proteins
showed sex differences in the cerebellum in controls.
Trisomy differentially affected protein levels in females
and males. In female trisomic mice, levels of a total of
69 proteins differed from female controls; 62 were in-
creased in the cerebellum, while only 18 were perturbed
in the hippocampus. In contrast, in male Dp10 mice,
while levels of a total of 68 proteins were perturbed in at
least one brain region, 49 were elevated in the hippo-
campus and 21 were altered in the cerebellum; the ma-
jority decreased relative to male controls. In both
control and trisomic mice, cortex showed the fewest sex
differences: levels of only one protein differed in control
mice, and 13 and 8 were altered in female and male
Dp10, respectively. Because of the sex specificities of the
trisomy-induced perturbations, male and female Dp10
mice differed in levels of 15 proteins in hippocampus, 70
in the cerebellum, and 23 in the cortex, a very different
profile from their littermate controls.
Diversity of sex differences
The number of sexually dimorphic proteins is of interest
given that the entire protein set was selected from those
shown by mutational analysis to function in brain devel-
opment, ID or LM, to be components of pathways rele-
vant to these processes or to show abnormalities in brains
of patients or mouse models of DS or AD [18, 47].
Indeed, sexually dimorphic proteins in the hippocam-
pus of control mice include five ID proteins or their
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phosphorylated forms (DYRK1A, pRSK, GFAP, GLUR3,
and SHH) and an additional 14 mouse LM proteins and
those in trisomic mice include four ID (NR1, NR2B,
pBRAF, and pFMRP) and five LM proteins. While the
consequences of a mutation that alters or eliminates the
function of an ID or LM protein likely will be different
from a simple change in protein level, when so many
learning/memory proteins differ in levels, the conse-
quences could be significant because they impact so many
downstream processes.
In both controls and trisomic mice, proteins showing
sex differences are diverse in their functional classifica-
tions. They include subsets of the components of the
MTOR, MAPK, and apoptosis pathways, in control
mice, several AMPA receptor subunits, and in trisomic
mice, NMDA receptor subunits. The cerebellum of tri-
somic mice shows the most dramatic sex differences,
with the magnitudes of the differences, averaging >30 %,
greater than in those in other genotype/brain regions.
These are due to the sensitivity of female mice to tri-
somy of the Dp10 segment, where 62 proteins differ
from control females, compared to only 21 in male
Dp10.
Sex differences were also seen in levels of proteins
with previously reported abnormalities in brains of pa-
tients with AD or mouse models [47]. Ten of these pro-
teins were significantly higher in the hippocampus of
control females than males. Because the majority of the
original mouse experiments used only males, for some
of these 26 proteins, interpretations regarding the sig-
nificance of observed increases and decreases may need
to be revisited after analysis of female mice is carried
out. In this vein, it is of interest to note that, among pro-
teins elevated in female controls is the amyloid precur-
sor protein, APP, that has been shown to cause AD in
families carrying a genomic duplication of the gene. Un-
derstanding the causes and consequences of naturally el-
evated levels in females may aid in understanding the
Fig. 6 Correlation of levels of MTOR pathway components across brain regions. Correlation coefficients for proteins in each brain region and sex/
genotype were determined using Spearman correlation analysis. Networks include only those protein pairs with r > 0.8 and p < 0.05, after manual
inspection to exclude spurious linearities. Red correlations in hippocampus, blue cerebellum, green cortex, black all three brain regions. a Male
controls. b Male Dp10. c Female controls. d Female Dp10
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role of elevated APP, not only in familial AD cases, but
also in DS.
Comparison with sex differences in mRNA expression
A comprehensive study of sex differences in gene ex-
pression at the RNA level found that 14 % of mRNAs
expressed in the brain differed in levels between females
and males [15]. This contrasts with the 40–50 % differ-
ences in protein expression identified here. This is not
unreasonable because the oligonucleotide arrays are an
unbiased screening of “all” transcripts, while proteins
here represent a very biased selection, and also include
31 with specific post-translational modifications. How-
ever, while transcripts encoding many RPPA proteins
were detected in [15], there were no overlaps between
RNAs showing sex differences and the proteins identi-
fied here. Because the whole brain was used in the RNA
study, many sex differences specific to the hippocampus,
cerebellum, or cortex, such as observed here, would be
missed, and indeed, the authors concluded that 14 %
was probably a low estimate [15]. In a more recent
paper, mRNA levels of 27 “mood-related” genes were ex-
amined in the frontal cortex of mice exposed to chronic
mild stress [51]. Genes included several involved in
GABA, serotonin, and dopamine signaling, and among
them were APP, CDK5, BDNF, and AKT that were mea-
sured here. Sex differences were seen but because the
mice were examined only after exposure to chromic
stress [51], comparisons with data from naïve mice here
are not meaningful. Lastly, because numerous regulatory
mechanisms govern post-transcriptional, translational,
and post-translational processes, relative RNA levels do
not reliably predict differences in protein levels [52, 53].
Comparison with sex differences in mutant phenotypes
Several proteins assayed here have been shown individu-
ally to contribute to sex-specific phenotypic features, at
least when mutated. For example, in an AD-related
study, when a FYN kinase null mutant was crossed with
the AD “triple transgenic” model (a mouse expressing
mutated forms of APP, Tau, and PSEN1), male offspring
were delayed in the development of Aβ pathology and
spatial learning deficits, while female offspring showed
no such temporal protection, i.e., decreased levels of
FYN were protective only in males [54]. Another study
showed that male mice were affected by the knockout of
the AMPAR subunit, GLUR1, as measured by impaired
retention in CFC, while female mice were unaffected
[55]. In mice deficient for the transcription factor CREB,
females were more negatively affected than males, show-
ing impairment in an easier LM task and at an earlier
age than males [56]. In a knockdown of NR1, male mice
showed impaired working memory in the Y maze as
early as 6 weeks of age, while female mice remained
unimpaired at 12 weeks [57]. Each of these proteins or
paralogs showed sex differences here in controls (FYN,
GLUR2-4, NR1, NR2B) or showed sex differences in re-
sponse to trisomy (FYN, GLUR2-4, CREB, NR1, NR2A,
NR2B). Although the differences were generally ~10–50 %,
and often were increases, and not the complete or hetero-
zygous knockout, their consequences for sex differences in
the molecular pathways subserving normal learning and
memory, and how these are perturbed in DS, require fur-
ther investigation.
Relevance to drug responses
Sex differences are also relevant to molecular responses
to drug treatments. The effects of fluoxetine were exam-
ined in rats that had been exposed to chronic stress.
When initially evaluated in the forced swim test, stressed
male rats showed increased immobility while stressed fe-
males showed increased hyperactivity. In both sexes,
stress response behavior was normalized by fluoxetine
[58]. Levels of ERK, p38, and JNK and their phosphory-
lated forms were measured in cytosolic and nuclear frac-
tions of the hippocampus. Complex and sex-specific
changes in levels and subcellular distributions of these
proteins occurred in response to stress and to fluoxetine
[58, 59]. So, while behavioral outcomes appeared to be
the same in male and female animals, the molecular
pathways to achieving this common result clearly dif-
fered between sexes. Levels of these same proteins dif-
fered here between sexes in control mice and in their
perturbations in trisomy. Fluoxetine is of interest in DS
because it has been shown to rescue LM deficits in an-
other mouse model of DS, the Ts65Dn [60–62]. Two
points require consideration. First, the Ts65Dn are triso-
mic for a completely different set of Hsa21 orthologs
than are the Dp10 mice. Thus, in full trisomy Hsa21
(i.e., >95 % of individuals with DS), the responses to flu-
oxetine, at least at the molecular level, will most likely
be different from those in the Ts65Dn because of influ-
ences of the Mmu10 orthologs. If, or how, this would
affect behavioral outcomes is a complete unknown. Sec-
ond, while male and female mice were used in the
Ts65Dn fluoxetine experiments, and efficacy was re-
ported to show no sex differences, the number of ani-
mals per group was typically small (often a total, males
plus females, of only four to six individuals), so that sig-
nificant sex differences would be difficult to detect.
Given our limited knowledge of sex differences at the
molecular level, and in drug responses, it is premature
to pool sexes in data analysis, especially in proposing
clinical trials for cognition in ID. No experimental data
are available in any DS mouse model regarding sex dif-
ferences in molecular responses to any drug currently in
or proposed for clinical trials [63]; these responses may
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differ, not only in full trisomy vs. in different partial tri-
somy mouse models but also in females vs. males.
Molecular contributions to sex and genotype differences
Sex hormones, X chromosome genes that escape inacti-
vation, and environmental effects all may contribute to
the sexually dimorphic patterns of protein expression
observed here in control mice. That these patterns are
different in Dp10 mice suggests that trisomic Mmu10
genes impact one or more of these normal processes.
Based on the known functions of Mmu10 trisomic genes,
candidates for perturbations of sex differences in expres-
sion can be proposed (although we note that levels of
gonadal hormones were not measured). Figure 7a shows a
network of protein interactions connecting Dp10 trisomic
genes with estrogen, progesterone, androgen, and thyroid
hormone receptors. The protein methyltransferase,
PRMT2, is of particular interest because it directly modi-
fies and activates ESR1, ESR2, PGR, and THRB and indir-
ectly affects AR [41, 42]. In the cerebellum, levels of
PRMT2 in female controls were 25 % lower than those in
male controls; trisomy served to increase PRMT2 levels in
females by >90 % and decrease them in males by >30 %.
Functional consequences for the cerebellum in DS are of
interest because of well-documented abnormalities in DS
regarding volume and cell numbers [64, 65]. Cerebellar
Fig. 7 Protein interaction networks. Protein interactions, retrieved from curated public databases, are indicated by lines connecting two nodes.
Nodes are color-coded: yellow Hsa21-encoded protein, red human ID protein [18], orange mouse LM protein (The Mammalian Phenotype
Database). a Interactions between Hsa21 proteins and sex or thyroid hormone receptors (blue); heavy lines direct interactions with a Dp10 protein.
b Interactions of RPPA proteins (green) that showed an abnormal level in at least one brain region/sex/genotype with X chromosome-encoded
proteins (blue) that escape silencing by X inactivation [10–12]. Arrows indicate activation in the MTOR pathway
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function is relevant, not only to motor control but also to
higher cognitive functions related to language and execu-
tive function [66, 67]. The Hsa21-encoded small
ubiquitin-like protein, SUMO3, modifies the nuclear re-
ceptor co-repressor, NCOR2 which in turn inhibits the ac-
tivities of ESR1, ESR2, PGR, and AR [42, 68]. Levels of
SUMO3 were not measured here, but where both SUMO3
and PRMT2 are overexpressed, the consequences for
regulation of activity levels of the hormone receptors will
further complicate predictions for phenotypic features in
DS. Information on the Dp10 regarding cellular/structural
cerebellar abnormalities is currently lacking.
Knockouts of two genes trisomic in the Dp10 have
been shown to be associated with sex-specific pheno-
types. TRPM2, a calcium-permeable cation channel pri-
marily activated by intracellular adenosine-diphosphate
ribose (ADPR) [69, 70], shows enhanced activation with
exposure to hydrogen peroxide and elevated oxidative
stress and leads to cell death. Knockout of the TPRM2
protects male, but not female, mice from effects of is-
chemia, and interaction with the AR through PARP1 has
been proposed as the mechanism [71, 72]. Elevated
levels of oxidative stress have been well documented in
DS [73], implicating a contribution from TRPM2 overex-
pression. In addition, hyperactivation of TRPM2 chan-
nels has recently been implicated as a downstream
consequence of Aβ increases in the AD brain and as a
mechanism contributing to cerebrovascular pathologies
in AD [74]. These latter experiments were conducted
only in male mice. Possible sex differences in these fea-
tures in DS need to be considered.
Not included in Fig. 7a but also showing sex differ-
ences is the adenosine deaminase, ADAR2, that edits
pre-mRNAs encoding several glutamate receptor sub-
units and a serotonin and a GABAA receptor subunit
[31–33]. Editing alters the amino acid sequence in these
substrates, consequently modulating receptor functional
properties and activity levels. Knockout of ADAR2 in
control mice was shown to impair hearing and the
acoustic startle response in male mice but leave females
unaffected [34]. The molecular mechanisms producing
this phenotype are not known. ADAR2 levels were ele-
vated by 50 % in the hippocampus of male, but not fe-
male Dp10 mice.
In humans, although it has been consistently shown
that ~15 % of X chromosome genes escape inactivation,
the consequences for protein levels have not been well
characterized. The number and identity of the genes
expressed from both X chromosomes, and the resulting
mRNA levels, varies among individuals and between tis-
sues/cell types [10–15, 75–78]. In mouse, fewer X
chromosome genes, ~3–7 %, have been reported to es-
cape inactivation [79]. It is not possible to generalize the
consequences for sex differences in the total proteome
or to extend observations in mouse to human; however,
some possibilities are illustrated in Fig. 7b. The network
includes X chromosome-encoded proteins that escape
inactivation in humans and interact with APP and com-
ponents of the MTOR pathway, each of which showed
sex differences here in control mice or perturbation in
trisomy. This would predict a molecular contribution to
sex differences in protein expression in humans, with
the potential for novel sex-specific differences in DS, fea-
tures that can be explored in future experiments.
Environmental conditions can also influence gene expres-
sion, potentially contributing to sex or genotype differences.
General environmental conditions are controlled, e.g., all
mice are exposed to the same level and frequency of noise,
light/dark cycle, and access to food and water. In addition,
all mice were sacrificed between noon and 2 p.m. to control
for normal circadian variations in protein expression. How-
ever, if there are sex or genotype differences in sensitivity to
any of these features, some (generally unpredictable) part of
the proteome would be affected. Behavioral studies are ne-
cessary to determine if the Dp10, males or females, are dif-
ferentially affected by environmental conditions of noise or
handling or if they exhibit altered sleep/wake or feeding
patterns.
An additional environmental influence on the prote-
ome arises from housing conditions and potential effects
of social hierarchy. A dominant male would have higher
levels of androgens than a submissive male, with down-
stream consequences for some protein expression. All
mice here were housed with their littermates of the same
sex. Because we did not ascertain the effects of trisomy
on the propensity for dominance, there are three pos-
sible scenarios: (i) control and Dp10 males are equally
likely to be the dominant animal, (ii) controls will always
be dominant over a Dp10, or (iii) a Dp10 will always be
dominant over a control. Given the number of each
genotype in each of the seven litters (Additional file 1),
at most six control mice or five Dp10 mice could be
dominant in any scenario. In test calculations, we as-
sumed that dominance results in a 50 % increase (direct
or indirect) in the level of protein A; in no case could
this produce a difference between controls and trisomy
that is significant after correction for multiple testing
(data not shown). We therefore conclude that none of
the differences we report is falsely attributed to genotype
instead of dominance. However, by the same calcula-
tions, a 50 % difference that is due to dominance could
be sufficient to mask a true genotype difference of the
magnitudes observed here, if the genotype difference is
opposite in direction (data not shown). By this reasoning
therefore, it is possible that there are actually more pro-
teins perturbed in trisomy than we detected. To our
knowledge, there have been no comprehensive protein
profiles generated from dominant vs. submissive mice.
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In future experiments where social hierarchy is consid-
ered, it will be of interest to ascertain the nature and
magnitude of effects on the protein set queried here.
Implications for sex differences in DS
While sex differences in the typical population in cogni-
tive strengths, neuropsychiatric disease incidence and se-
verity, and drug responses have been well documented,
little is known about the molecular correlates of the dif-
ferences. Sex differences in the same features in people
with DS, and whether they simply reflect those in the
typical population, have not been commonly reported
[80]. However, there are reports to suggest that this
should be explored. For example, examination of the re-
cords of >1300 individuals with DS spanning 1953–2000
found that life span for females was significantly shorter
than for males (<58 vs. >61 years, respectively) [81]. This
is opposite to the typical population and to a population
with ID not due to DS. There is evidence that sex differ-
ences in cognitive profiles exist in DS. In assessments
carried out over a span of 7 years of a cohort of people
with DS with similar mean IQ levels (~40), females out-
performed males on a subset of tests from the Wechsler
Intelligence Scale [82]. This observation is supported
and extended in results from a recent comprehensive
analysis of adults with DS; women performed signifi-
cantly better than men on several evaluations including
those for memory and executive function [83]. A chal-
lenge in many cellular/molecular studies is small sample
size. For example, the intriguing results characterizing
cerebellar deficits in cell proliferation [84] examined
only three females and four males, too few for reliable
detection or exclusion of sex differences. A few studies
using the Ts65Dn mouse model of DS have shown sex
differences. Female Ts65Dn were shown to have lower
numbers of the basal forebrain cholinergic neurons [85],
and sex differences in anxiety after exposure to preda-
tors have been reported [86]. These examples obviously
are neither comprehensive nor even very extensive. It
should not be assumed, therefore, that sex differences in
DS, in particular in cognitive performance, and in mech-
anisms to cope with stress and anxiety that can impact
cognitive performance, are insignificant DS or not differ-
ent from the typical population, until a concerted effort
to identify them is carried out.
Conclusions
The number and nature of significant perturbations in
protein expression in 8-month-old Dp10 mice contrasts
with the report of no LM deficits in 2–4-month-old
(male) Dp10 [23]. These disparate observations could be
explained if the protein abnormalities are age-dependent
and absent in younger mice. If this is true, it will be of
interest to determine if the protein abnormalities at
8 months also reflect an age-dependent development of
LM deficits. Experiments to address these possibilities are
in progress. If, however, these protein abnormalities are not
associated with LM deficits, an alternate explanation is that
one or more trisomic proteins directly or indirectly act to
protect the Dp10 from the deleterious effects of overexpres-
sion of other trisomic genes, i.e., the constellation of mo-
lecular abnormalities seen here is a sum of deleterious
effects and neutralizing, compensatory responses. This sce-
nario would have consequences for full trisomy Hsa21,
where trisomy of Mmu10 orthologs could influence the DS
phenotype and responses to drug treatments. It remains
possible, of course, that none of the products of the Dp10
trisomic genes, individually or collectively, or the observed
downstream abnormalities, negatively perturbs neurological
function. This would, however, be surprising, given the
known roles of many of these proteins in molecular and
cellular processes underlying normal LM and ID. The in-
volvement of Hsa21 proteins shown in Fig. 7, i.e., PRMT2,
SUMO3, S100B, TRPM2, in modulating activities of thy-
roid, estrogen, and other sex hormone receptors, and in in-
teractions with many ID proteins certainly suggests sex
differences may well exist in DS, with the consequence that
sex differences in drug responses could also be significant.
Further experiments are clearly necessary to compare not
only protein expression consequences but also behavioral
and drug responses of the Mmu10 trisomic region in the
presence of trisomy of the Mmu16 and Mmu17 regions.
While the extents of the sex differences in controls and
Dp10 mice may be surprising, they are entirely consistent
with and supportive of past [87] and more recent
calls [88, 89] for inclusion of females in both cell and ani-
mal studies in general and preclinical evaluations of drug
treatments in particular. It is important to determine how
results here in mice extend to humans.
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